OTC Private Label Anchors Perrigo Amid Branded Business Turmoil
This article was originally published in The Tan Sheet
Executive Summary
CEO John Hendrickson and CFO Judy Brown reassure investors that Perrigo's US OTC private label platform supports the firm as it makes changes to turn around its European branded product business that stumbled soon after being put together.
You may also be interested in...
Perrigo's Return To OTC Roots Restoring Investor Confidence
The OTC drug, infant and adult nutritionals, Rx generic topicals and API manufacturer's share price has been up since it re-stated is historical revenues from Tysabri multiple sclerosis treatment royalties and reported interim 2017 first-quarter results. Perrigo will "fully concentrate on growing" OTC portfolio.
Perrigo's Return To OTC Roots Restoring Investor Confidence
The OTC drug, infant and adult nutritionals, Rx generic topicals and API manufacturer's share price has been up since it re-stated is historical revenues from Tysabri multiple sclerosis treatment royalties and reported interim 2017 first-quarter results. Perrigo will "fully concentrate on growing" OTC portfolio.
Perrigo Shareholder Lawsuits Claim Joining Mylan Was A Better Idea
Two complaints seeking compensation for Perrigo shareholders and four motions seeking lead plaintiff designations in the litigation have been filed in US district court. Both target Perrigo's fundamental argument against Mylan's takeover bid in 2015, that the company would be stronger continuing on its own.